Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma

BACKGROUND: Patients with severe, uncontrolled asthma experience debilitating symptoms that result in meaningful reductions to health-related quality of life. Benralizumab is an interleukin-5 receptor alpha–directed cytolytic monoclonal antibody that reduces exacerbations and improves asthma symptom...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Quinn, Sean, Xu, Xiao, Hirsch, Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350639/
https://www.ncbi.nlm.nih.gov/pubmed/30774388
http://dx.doi.org/10.2147/JAA.S190221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350639/
https://www.ncbi.nlm.nih.gov/pubmed/30774388
http://dx.doi.org/10.2147/JAA.S190221

Ejemplares similares